A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. We are advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including Friedreich ataxia, or FA, cardiomyopathy, plakophilin-2, or PKP2, arrhythmogenic cardiomyopathy, and other devastating diseases with high unmet need. Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial. In July 2024, we provided an interim clinical update, which included baseline characteristics from 11 treated participants across the two studies and data from 8 participants who had reached at least 6-months of follow-up as of that time.
| Metric | TTM | FY2022 |
|---|---|---|
| Revenue | 0 | - |
| Net Income | -105M | -59M |
| EPS | $-2.50 | $-36.36 |
| Free Cash Flow | 0 | -55M |
| ROIC | -112.3% | -49.2% |
| Gross Margin | - | - |
| Debt/Equity | 0.00 | -0.01 |
| Dividends/Share | $0.00 | - |
| Operating Income | -114M | -61M |
| Operating Margin | 0.0% | - |
| ROE | -86.9% | - |
| Shares Outstanding | 73M | 27M |
| Metric | 2022 | |
|---|---|---|
| Income Statement | ||
| Revenue | N/A | 0 |
| Gross Margin | N/A | N/A |
| R&D | N/A | N/A |
| SG&A | N/A | N/A |
| EBIT | -61M | -114M |
| Op. Margin | N/A | 0.0% |
| Net Income | -59M | -105M |
| Net Margin | N/A | 0.0% |
| Non-Recurring | 0 | 0 |
| Returns on Capital | ||
| ROIC | -49.2% | -112.3% |
| ROE | N/A | -86.9% |
| ROA | -61.1% | -73.0% |
| Cash Flow | ||
| Op. Cash Flow | -55M | -107M |
| Free Cash Flow | -55M | 0 |
| Owner Earnings | -56M | -109M |
| CapEx | 672K | 0 |
| Maint. CapEx | 120K | 120K |
| Growth CapEx | 552K | 0 |
| D&A | 120K | 120K |
| CapEx/OCF | N/A | 0.0% |
| Capital Allocation | ||
| Dividends Paid | 0 | 0 |
| Dividend Yield | N/A | N/A |
| Share Buybacks | 0 | 0 |
| Buyback Yield | N/A | 0.0% |
| Stock-Based Comp | 1.8M | 1.8M |
| Debt Repayment | 0 | 0 |
| Balance Sheet | ||
| Net Debt | -76M | -41M |
| Cash & Equiv. | N/A | 41M |
| Long-Term Debt | 1.6M | 1.6M |
| Debt/Equity | -0.01 | 0.00 |
| Interest Coverage | -664.9 | -664.9 |
| Equity | -113M | 121M |
| Total Assets | 97M | 144M |
| Total Liabilities | 25M | 23M |
| Intangibles | N/A | N/A |
| Retained Earnings | -115M | -115M |
| Working Capital | 66M | 66M |
| Current Assets | 80M | 80M |
| Current Liabilities | 14M | 14M |
| Per Share Data | ||
| EPS | -36.36 | -2.50 |
| Owner EPS | -2.12 | -1.49 |
| Book Value | -4.24 | 1.66 |
| Cash Flow/Share | -2.05 | -1.44 |
| Dividends/Share | N/A | 0.00 |
| Shares Out. | 26.7M | 73.0M |
| Valuation | ||
| P/E Ratio | N/A | -2.7 |
| P/FCF | N/A | N/A |
| EV/EBIT | N/A | N/A |
| Price/Book | N/A | 4.0 |
| Price/Sales | N/A | N/A |
| FCF Yield | N/A | N/A |
| Market Cap | N/A | 487M |
| Avg. Price | N/A | 6.67 |
| Year-End Price | N/A | 6.67 |
Lexeo Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Lexeo Therapeutics, Inc. (LXEO) has a 5-year average return on invested capital (ROIC) of -49.2%. This is below average and may indicate limited pricing power.
Lexeo Therapeutics, Inc. (LXEO) has a market capitalization of $487M. It is classified as a small-cap stock.
Lexeo Therapeutics, Inc. (LXEO) does not currently pay a regular dividend.
Lexeo Therapeutics, Inc. (LXEO) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Lexeo Therapeutics, Inc. (LXEO) generated $-55 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Lexeo Therapeutics, Inc. (LXEO) reported earnings per share (EPS) of $-36.36 in its most recent fiscal year.
The Ledger Terminal provides 1 years of financial data for Lexeo Therapeutics, Inc. (LXEO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Lexeo Therapeutics, Inc. (LXEO) has a book value per share of $-4.24, based on its most recent annual SEC filing.